Hormone Receptor-positive, Her2-negative Locally Advanced or Metastatic Breast Cancer in Combination with Fulvestrant as Initial Endocrine-based Therapy or Following Prior Endocrine Therapy

Hormone Receptor-positive, Her2-negative Locally Advanced or Metastatic Breast Cancer in Combination with Fulvestrant as Initial Endocrine-based Therapy or Following Prior Endocrine Therapy is a serious health matter that can affect many aspects of life. The medicines listed here including Ribociclib represent options that a clinician may discuss. Products containing Ribociclib feature in this group.